ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) granted an inducement stock option to Jeff Knight, Chief Development and Operating Officer, consisting of 800,000 shares on April 16, 2026.
The option has an exercise price of $1.68 (equal to the closing price on the grant date) and vests 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly thereafter under the 2025 Inducement Equity Incentive Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
On the day this news was published, ALXO gained 4.79%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALXO was flat while peers were mixed: ARTV +34.74%, INKT +9.7%, CUE -6.38%, with others modestly negative, suggesting stock-specific rather than sector-driven dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Executive appointment | Positive | +2.9% | Appointed Jeff Knight as Chief Development and Operating Officer. |
| Feb 27 | Earnings and update | Positive | -10.2% | Reported 2025 results, extended cash runway and outlined clinical milestones. |
| Feb 19 | Investor conferences | Positive | +12.1% | Announced participation in multiple Q1 2026 investor conferences and webcasts. |
| Feb 19 | Earnings date | Neutral | +12.1% | Set date and call details for Q4 and full‑year 2025 results. |
| Jan 30 | Equity offering | Neutral | +10.8% | Priced underwritten equity offering to raise about $150M for key programs. |
Recent news often drew positive price reactions, except for a negative move on financial results despite balance sheet improvement.
Over recent months, ALXO combined financing, corporate updates, and investor outreach. A late‑January underwritten offering raised capital for evorpacept and ALX2004. February brought earnings and a corporate update alongside conference participation and an earnings date announcement. In April, the company appointed Jeff Knight as Chief Development and Operating Officer. Today’s inducement grant ties directly to that executive hire, extending the same governance and compensation theme.
Market Pulse Summary
This announcement details an inducement stock option grant of 800,000 shares at $1.68 per share for ALXO’s new Chief Development and Operating Officer, formalizing terms previously flagged in SEC filings. It extends a pattern of equity-based incentives used to attract and retain key talent. Investors may track future disclosures on additional grants, overall share count evolution, and how new leadership supports milestones for the company’s oncology pipeline.
Key Terms
inducement stock option financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight’s inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock option has an exercise price of
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028
